News
Article
Author(s):
LEO Pharma expected to expand Spevigo developments as well as improve access to care.
The transaction is expected to officially close in the second half of 2025, subject to merger control clearances.
Stock.adobe.com
Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy therapies, announced a $105 million (€90 million) global license and transfer agreement with LEO Pharma for the generalized pustular psoriasis (GPP) treatment Spevigo.
LEO Pharma, global leaders in medical dermatology specializing in skin health solutions, entered into an agreement with Boehringer Ingelheim on an exclusive global licensing and transfer agreement, for the commercialization and development of Spevigo.
“Skin diseases can profoundly impact people’s lives––and at LEO Pharma, we are here to change that,” said Christophe Bourdon, CEO of LEO Pharma. “Partnering to bring Spevigo to more patients is more than a strategic step––it means the opportunity to help people living with GPP by addressing a disease with limited treatment options and aiming to improve their quality of life. We are inspired by Boehringer Ingelheim’s pioneering efforts and thrilled to build on that foundation. Together, we have a powerful opportunity to expand access to innovative care and deliver meaningful progress for patients who have long been underserved.”1
The transaction is expected to officially close in the second half of 2025, subject to merger control clearances. As agreed, Boehringer Ingelheim is set to receive an upfront payment of 105 million, with additional royalties and milestone payments.
This also marks the second partnership LEO Pharma has signed in 2025. In January, the company struck a $1.7 billion deal with Gilead for a portion of the company’s STAT6 transcript factor program.
As agreed, upon in their deal with Boehringer Ingelheim, the medical dermatology company will be responsible for the commercialization and advancement of developments for Spevigo. LEO Pharma is expected to leverage its global commercial platform to assist in disease awareness and access to patient care for GPP.
“We are immensely proud of what Spevigo represents for people living with GPP and bringing innovation to this community of patients has been a powerful reflection of our purpose to transform lives,” said Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. “Spevigo holds a significant promise, and ensuring it reaches its full potential requires continued focus, and expertise in medical dermatology. With over six decades of singular dedication to this field, LEO Pharma is exceptionally well-positioned to build on the strong foundation we’ve laid. We remain profoundly grateful to the patients, caregivers, and healthcare professionals who have walked this journey with us.”1
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
